Kiniksa Pharmaceuticals International, plc
KNSA
$40.59
$0.521.30%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 180.86M | 156.80M | 137.79M | 122.54M | 112.21M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 180.86M | 156.80M | 137.79M | 122.54M | 112.21M |
| Cost of Revenue | 83.56M | 71.02M | 61.66M | 66.09M | 49.42M |
| Gross Profit | 97.29M | 85.78M | 76.13M | 56.45M | 62.80M |
| SG&A Expenses | 49.10M | 46.86M | 43.53M | 40.54M | 46.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 156.83M | 136.64M | 124.51M | 141.84M | 121.87M |
| Operating Income | 24.02M | 20.16M | 13.27M | -19.30M | -9.66M |
| Income Before Tax | 27.16M | 22.88M | 15.57M | -16.98M | -7.20M |
| Income Tax Expenses | 8.72M | 5.05M | 7.03M | -8.09M | 5.49M |
| Earnings from Continuing Operations | 18.44M | 17.83M | 8.54M | -8.89M | -12.69M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.44M | 17.83M | 8.54M | -8.89M | -12.69M |
| EBIT | 24.02M | 20.16M | 13.27M | -19.30M | -9.66M |
| EBITDA | 24.41M | 20.52M | 13.62M | -18.90M | -9.26M |
| EPS Basic | 0.25 | 0.24 | 0.12 | -0.12 | -0.18 |
| Normalized Basic EPS | 0.23 | 0.19 | 0.13 | -0.15 | -0.06 |
| EPS Diluted | 0.23 | 0.23 | 0.11 | -0.12 | -0.18 |
| Normalized Diluted EPS | 0.21 | 0.18 | 0.13 | -0.15 | -0.06 |
| Average Basic Shares Outstanding | 74.71M | 73.44M | 72.65M | 72.32M | 71.73M |
| Average Diluted Shares Outstanding | 80.04M | 77.94M | 76.15M | 72.32M | 71.73M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |